The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickn…

Motion Sickness, SpaceMotion SicknessSea Sickness

~Estimated

~$10 – $8,750

Repurposed Therapeutics, Inc.NCT05886660

Phase 2

Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance. Motion Sickness Countermeasures Field Test

The primary specific aim of this Field Test aim is to evaluate the feasibility and efficacy of administering the intranasal scopolamine gel in operational fiel…

Motion Sickness, SpaceMotion SimulationParabolic Flight

~Estimated

~$10 – $8,750

Repurposed Therapeutics, Inc.NCT05852730